- Home
- AGIO vs FORTY Comparison
AGIO vs FORTY Comparison
Compare AGIO & FORTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- FORTY
- Stock Information
- Founded
- AGIO 2007
- FORTY 1985
- Country
- AGIO United States
- FORTY Israel
- Employees
- AGIO N/A
- FORTY N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- FORTY EDP Services
- Sector
- AGIO Health Care
- FORTY Technology
- Exchange
- AGIO Nasdaq
- FORTY Nasdaq
- Market Cap
- AGIO 1.4B
- FORTY 1.3B
- IPO Year
- AGIO 2013
- FORTY 1997
- Fundamental
- Price
- AGIO $27.32
- FORTY $97.11
- Analyst Decision
- AGIO Buy
- FORTY
- Analyst Count
- AGIO 8
- FORTY 0
- Target Price
- AGIO $56.00
- FORTY N/A
- AVG Volume (30 Days)
- AGIO 524.5K
- FORTY 603.0
- Earning Date
- AGIO 05-01-2025
- FORTY 05-21-2025
- Dividend Yield
- AGIO N/A
- FORTY 1.56%
- EPS Growth
- AGIO N/A
- FORTY 23.49
- EPS
- AGIO 11.45
- FORTY 5.09
- Revenue
- AGIO $37,035,000.00
- FORTY $2,757,511,000.00
- Revenue This Year
- AGIO $40.62
- FORTY N/A
- Revenue Next Year
- AGIO $216.26
- FORTY N/A
- P/E Ratio
- AGIO $2.39
- FORTY $18.50
- Revenue Growth
- AGIO 25.96
- FORTY 5.21
- 52 Week Low
- AGIO $23.42
- FORTY $69.07
- 52 Week High
- AGIO $62.58
- FORTY $100.00
- Technical
- Relative Strength Index (RSI)
- AGIO 41.34
- FORTY 72.48
- Support Level
- AGIO $27.78
- FORTY $85.30
- Resistance Level
- AGIO $31.55
- FORTY $87.57
- Average True Range (ATR)
- AGIO 1.38
- FORTY 1.50
- MACD
- AGIO -0.03
- FORTY 0.79
- Stochastic Oscillator
- AGIO 2.98
- FORTY 55.49
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About FORTY Formula Systems (1985) Ltd.
Formula Systems (1985) Ltd is a holding company that, through its subsidiaries, provides information technology services. The company organizes itself into operating segments: The Matrix segment, which generates the majority of revenue, provides software development and existing software expansion services. The Sapiens segment provides software development services for the insurance industry. The Magic Software segment provides vendor management systems and workforce management services, which include accounting and finance, human resources; Michpal; ZAP Group and Others. The majority of the company's revenue comes from Israel.